Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results on July 24, 2026 Alzheimer 's disease BIIB080 Biogen CELIA Clinical Research diranersen Mental deterioration Phase 3 trials tau-targeting drug uridine triacetate +
AAIC 2026：Biogen公布抗tau反义寡核苷酸药物详细数据，抗tau领域初现曙光 on July 15, 2026 AAIC Biogen diranersen Pet Animal uridine triacetate +
Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results on July 15, 2026 Alzheimer 's disease Biogen CDR-SB CELIA Phase 2 trial diranersen dose-response Low dose Mental deterioration Pathology Phase 3 questions uridine triacetate +
AAIC 2026: Tau-targeted Alzheimer treatments heat up while amyloid therapies persist on July 13, 2026 anti-amyloid therapies Bepranemab BIIB080 diranersen Donanemab E2814 etalanetug Kisunla Lecanemab tau-targeted therapies VY1706 gene therapy +
Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results on May 15, 2026 Alzheimer 's disease Biogen CELIA diranersen Ionis Pharmaceuticals Mental deterioration Phase 2 trial registrational development uridine triacetate +
Biogen advances Alzheimer’s tau program despite midphase miss on May 14, 2026 Benefit Biogen Biological Markers Cognitive diranersen Phase 2 Phase 3 registrational development uridine triacetate +